newsfilter
← Latest News
Business Wire·

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

A

Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab) Agilent Technologies Inc. (NYSE:A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3